Functional genomics resources for the Drosophila and broader research communities

项目总结--总体 我们将在现有的基础设施、专业知识和记录的基础上，成立果蝇研究和 筛选中心-生物医学技术研究资源(DrSc-BTRR)。我们的总体目标将是帮助 研究人员认识到果蝇作为研究人类健康和疾病的模型的全部潜力，以及 作为与医学相关的昆虫的模型，例如传播传染病的蚊子。DrSc-BTRR将 在三个技术领域开发最先进的工具和方法：(1)功能基因组学的发展 果蝇细胞和体内研究技术(包括CRISPR-CAS9技术)；(2) 功能基因组和蛋白质组技术在人类疾病蚊媒中的应用； 果蝇体内蛋白质组学技术研究进展。我们将通过以下方式开发技术 迭代的几轮开发、测试和改进，以及一系列推动生物医学项目 这可以从技术的应用中受益。为了进一步扩大这些技术的影响，我们将 参与社区活动，让广大受众了解情况并迅速将技术传播给其他人 确保长期使用的设施。总之，我们将作为一个综合的、协作的资源 在美国国立卫生研究院几个研究所感兴趣的领域开展有很大影响潜力的项目， 包括基础细胞和生物生物学、发育生物学、癌症治疗学、稀有遗传学 疾病和蚊子传播的疾病。

PROJECT SUMMARY – OVERALL We will build on our existing infrastructure, expertise, and track-record to form the Drosophila Research and Screening Center-Biomedical Technology Research Resource (DRSC-BTRR). Our overall goal will be to help researchers realize the full potential of Drosophila as a model for the study of human health and disease, and as a model of medically-relevant insects such as mosquito vectors of infectious disease. The DRSC-BTRR will develop state-of-the-art tools and methods in three technology areas: (1) development of functional genomics technologies for Drosophila cell-based and in vivo studies (including CRISPR-Cas9 technologies); (2) application of functional genomic and proteomic technologies to mosquito vectors of human diseases; and (3) development of in vivo proteomics technologies for Drosophila. We will develop the technologies through iterative rounds of development, testing, and improvement together with a set of driving biomedical projects that can benefit from application of the technologies. To further extend the impact of the technologies, we will engage in community activities that inform a broad audience and rapidly disseminate technologies to other facilities to ensure long-term access. Altogether, we will serve as an integrated, collaborative resource engaging in projects with strong potential for impact in areas that are of interest to several NIH institutes, including fundamental cell and organismal biology, developmental biology, cancer therapeutics, rare genetic disorders, and mosquito-borne diseases.